Seeking Alpha

Goldman is out with an upbeat note on BioMarin (BMRN +0.2%) following Thursday's Q2 report, BMN...

Goldman is out with an upbeat note on BioMarin (BMRN +0.2%) following Thursday's Q2 report, BMN 673 update, and news of a BMN 111 partial clinical hold. Analyst Navdeep Singh says the company "is set up well for outperformance starting in late 2013" with a meaningful catalyst around the corner in the form of regulatory news for Vimizim. Price target is $76 based on an 85%/ 15% blend of a DCF-derived value and a theoretical M&A value.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|